Glutamic acid decarboxylase (GAD 65 ) has been implicated as a targeted self antigen in the immune destruction of pancreatic β cells. T cell responses to GAD 65 peptides have been detected in both patients with type I diabetes and in the non-obese diabetic (NOD) mouse. To establish which GAD 65 epitopes are important in the immunopathogenesis of disease we initially compared T cell responses to GAD 65 epitopes in conditions of disease susceptibility and protection. T cell responses to GAD 65 peptides were measured in monozygotic twin pairs selected on the basis of disease discordance and T cell recognition of immunogenic regions of GAD 65 . Peptides of interest were then used to immunize susceptible NOD mice and H2-E transgenic NOD mice which are protected from diabetes. A differential response to the epitope GAD 65 521-535 discriminated diabetic from non-diabetic human twins as well as susceptible from protected mice. This epitope as well as GAD 505-519 induces T cell responses despite binding the type I diabetes associated HLA-DQA1*0301/DQB1*0302 product with low affinity. Since DQ-restricted T cell responses are difficult to study in humans, HLA-DQ8 transgenic mice were then used: GAD epitopes 521-535 and 505-519 induced responses in DQ8 transgenic mice and T cell lines were established. Long-term T cell lines against GAD 505-519 were HLA-DQ restricted, and responded to peptide with a strong IFN-γ and IL-10 response. The findings implicate GAD 521-535 as a possible target peptide in pathogenesis and are compatible with a model whereby self-reactive T cells specific for low-affinity peptide-MHC complexes may escape thymic negative selection.
Introduction
CD4 ϩ T cell responses to GAD 65 are thought to be important in the pathogenesis of type I diabetes in humans and non-obese diabetic (NOD) mice (1) (2) (3) (4) . One region of GAD 65 in particular, encompassing amino acids 473-555, is dominantly recognized by T cells from patients with type I diabetes (1) . Epitopes within this region (GAD 65 509-528 and 524-543) are also immunodominant in NOD mice and are among the earliest islet cell components recognized during disease onset (3, 4) .
The NOD mouse spontaneously develops type I diabetes and is the best animal model for the human disease (5) . Transgenic NOD mice expressing an H2-E transgene in addition to endogenous expression of H2-A g7 are protected from insulitis and diabetes (6) . The degree of protection appears to increase with increasing H2-E expression (7, 8) . The underlying mechanism for protection is unknown, but could involve changes in thymic selection of the TCR repertoire, in the specificity of responses by determinant capture (9) and in the cytokine profile of responding T cells. Protection from diabetes can also be studied in humans since monozygotic twins are often discordant for type I diabetes with some non-diabetic twins at relatively low risk (10) .
Type I diabetes is strongly associated with HLA-DRA1*0101/ DRB1*0401 and HLA-DQA1*0301/DQB1*0302 in humans (11, 12) , while HLA-DQA1*0102/DQB1*0602 confers dominant protection (11) . Genetic analysis demonstrates that disease susceptibility in NOD mice is strongly linked to the presence of a H2-Aβ chain allele, H2-A g7 (5) . This H2-Aβ chain allele shares with the human insulin-dependent diabetes mellitus (IDDM)-associated DQβ chains the feature of a non-Asp residue at position 57, in this case serine, which profoundly influences the shape of the peptide binding groove (13) . It is uncertain how MHC molecules influence susceptibility to autoimmune disease. According to one model, alleles associated with disease preferentially bind immunodominant self peptides (14) . An example of this is an immunodominant epitope of myelin basic protein (MBP; amino acids 83-99) which binds well to multiple sclerosis associated HLA-DR alleles (15) . According to this selective binding model, the prediction of strong class II motifs should lead to the identification of epitopes recognized by self-reactive T cells (16) . There are, however, some autoimmune disease epitopes which are notable because of the weakness of their binding to the class II molecule implicated in disease (17, 18 ). An example of such an epitope is MBP Ac1-11, which in the context of H2-A u induces experimental allergic encephalomyelitis (EAE) in susceptible mice (17) . It has been proposed that low-affinity binding may prevent the induction of thymic self-tolerance by the absence of adequate negative selection to prevent autoreactive T cells being exported into the periphery (19) . In HLA-DR4 multiple sclerosis patients, the immunodominant MBP epitope, 111-129, binds DR4 with low affinity (20) . In this context, the weak and unstable peptide binding of H2-A g7 molecules in NOD mice and DQ8 in some diabetic patients could interfere with the elimination of autoreactive T cells and promote disease (21, 22) . This raises the question of whether low-affinity but immunodominant epitopes of GAD 65 promote autoreactive T cell responses because of a failure to produce tolerance during thymic development. Our approach has been to identify epitopes implicated in diabetes by comparison of T cell responses in susceptible and protected humans and NOD mice while also characterizing the key epitopes with respect to their binding affinity for HLA-DQ8 and their ability to stimulate responses in DQ8 transgenic mice.
Methods

Peptide synthesis
In total, 36 15mers overlapping by 11 residues covering the regions 161-243 and 473-555 of human GAD 65 were synthesized by the multipin method (23) . The following peptides were synthesized for murine studies, HLA binding assay and T cell clone analysis, on an automated peptide synthesizer, AMS 422 (ABIMED, Langenfeld, Germany) using Fmoc chemistry and purified by reverse-phase HPLC: human GAD 161-175, MHCQTTLKYAIKTGH; 505-519, CFWYIPPSL-RTLEDN; 521-535, ERMSRLSKVAPVIKA; 247-266, NMYAM-MIARFKMFPEVKEKG. The final purity was Ͼ90% as estimated by HPLC and mass spectrometric analysis as previously described (23) .
Patients
Patients, monozygotic twins and controls were selected from the British Diabetes Twin Study, the diabetes clinic at St Bartholomew's Hospital, London and the local community. Type I diabetes was defined according to the National Diabetes Data Group criteria. Monozygosity between twins was established as previously described (10) . All subjects were of European origin and diabetic patients had no diabetic complications or other diseases and Ͻ5 years' disease. Of 36 diabetic (16 twins) and 18 control (eight twins) subjects studied initially, we selected for epitope mapping six diabetic patients (five twins) and seven controls (five twins) who respond to GAD 65 473-555, immunodominant in diabetes, as well as region 161-243, immunodominant in controls (1). Twins came from five pairs discordant for diabetes in which the non-diabetic, with normal glucose tolerance and without islet cell or GAD antibodies, had an estimated Ͻ5% risk (10) . Subject characteristics are reported in Table 1 . In total, 36 15mer peptides were used to define responses to GAD 65 161-243 and 473-555. Age, HLA and other features of these individuals are reported in Table 1 . GAD antibodies were detected using a recombinant GAD assay (1) . Islet cell antibodies were measured by indirect immunofluorescence. HLA-typing was performed by serology using Xth HLA Workshop antibodies and an allele-specific PCR for HLA-DQ. The study was approved by the Ethical Committee of St Bartholomew's Hospital.
Primary T cell proliferation and T cell clones establishment in IDDM patients
The peripheral blood lymphocytes of the probands were separated by Ficoll-Hypaque (Lymphoprep; Nycomed, Oslo, Norway) density gradient centrifugation. After washing the cells twice in RPMI 1640 with glutamine (Gibco, Paisley, UK)/ 2.5% FCS the pellet was diluted in RPMI/10% autologous serum. Gentamycin (Gibco) was used at 50 µg/ml in all culture media. The proliferation assays were performed in 96-well round-bottomed plates (Nunc, Roskilde, Denmark) with 2ϫ10 5 cells/well in a final volume of 200 µl/well. Peptides were used at a final concentration of 5 µg/ml and negative controls contained the same dilution of peptide buffer without peptide. Tetanus toxoid (TT; Wellcome, Beckenham, UK) and phytohemagglutinin (PHA; Difco, East Molesey, UK) were used as positive controls. Sixteen wells for each peptide, 32 negative control wells and eight wells for both positive controls (PHA and TT) were plated. Culture were incubated at 37°C, 5% CO 2 atmosphere for 4-5 days. During the last 6 h 0.5 µCi [ 3 H]thymidine (Amersham, Little Chalfont, UK) per well was added before harvesting and scintillation counting using a betaplate counter (Wallac Turku, Finland). Responding individuals were defined as previously described, with frequencies of positive responses significant at the P Ͻ 0.0025 level reported (1, 23) . T cell clones specific for GAD 65 epitopes were established as previously described (24) .
Peptide binding assay
Isolation of DQ8 (DQA1*0301/ DQB1*0302) was performed as follows. Cell pellets from the LCL BSM were lysed and the resulting homogenates prepared for affinity chromatography using the mAb Tü 22 (anti-HLA-DQβ chain). Protein concentra-tion was determined by the method of Bradford, the purity was checked by SDS-PAGE, high-performance size-exclusion chromatography (HPSEC) and Western blotting using the HLA-DR mAb Tü 39 and the HLA-DQ mAb KN2/5B10D8 (kindly provided by C. Mueller, Tü bingen). The HPSEC competition assay was performed as described elsewhere (25, 26) . Briefly, solubilized HLA-DQ isolates (0.2 µM) were incubated for 40 h with the N-terminally fluorescently (AMCA) labeled positive control reference binding peptide (1.5 µM; CD20 249-262 for DQ3.2) and with various concentrations of unlabeled peptides in a 150 mM sodium phosphate buffer containing 15% (v/v) acetonitrile and 0.1% (w/v) Zwittergent 3-12. All samples were subsequently analysed using HPSEC. The UV absorbance at 214 nm and fluorescence at 350/450 nm were detected simultaneously. The competition curves of the unlabeled peptides were determined by comparing the corresponding F/UV values of each sample with an uncoupled reference sample.
Transgenic mice C57BL/10 and C57BL/10.DQ8 transgenic mice and NOD and NOD.E transgenic mice were bred and housed in the Biological Services Unit at the MRC Clinical Sciences Centre (Hammersmith Hospital, London). Female mice between the ages of 8 and 12 weeks were used. C57BL/10.DQ8 mice were generated by microinjection of genomic constructs for DQA1*0301 and DQB1*0302. The transgenic line has been maintained at the MRC Clinical Sciences Centre for Ͼ15 generations by crossing with C57BL/10 partners. Consequently no difference was observed between those experiments in which negative littermates were used as negative controls and those in which C57BL/10 mice were used. Transgenic mice were genotyped by PCR using DQA1*0301 and DQB1*0302 sequence-specific oligonucleotide primer pairs which do not cross-react with H-2A or other alleles of HLA-DQ to amplify tail biopsy DNA (27) . In our NOD colony, 80-90% of female mice succumb to diabetes by 6 months. In contrast NOD mice carrying a transgenic Ea d molecule allowing expression of an H-2E heterodimer do not develop diabetes (6) .
Northern analysis
Expression of the HLA-DQ transgenes was analysed by Northern analysis. Total RNA was prepared from spleen, thymus, kidney, lung, heart, brain and jejunum of transgenic mice and negative littermates using the acid phenol method (RNAzol B; Biogenesis, Poole, UK). Total RNA (10 µg) from each tissue was loaded on a 1% agarose/formaldehyde gel, electrophoresed and then blotted onto a Hybond N membrane (Amersham, UK) and probing with the 10.8 DQα PstI fragment probe as previously described (28) .
Immunocytochemistry
Spleen and thymus from HLA-DQ transgenic mice and negative littermates were embedded in OCT compound, snapfrozen in isopentane in liquid nitrogen and cut into 5 µm sections in a cryostat. Sections were fixed in acetone and incubated with first layer antibodies, biotinylated L2 (anti-DQα), anti-IgM, anti-mouse CD3, G8.8 anti-Gp40 EpCAM thymic medullary epithelium marker or CDR1 anti thymic cortical epithelium, followed by FITC-conjugated mouseadsorbed F(abЈ) 2 -anti-rabbit Ig (Jackson ImmunoResearch, West Grove, PA) or streptavidin-Texas Red (Vector, Peterborough, UK).
Flow cytometry
HLA-DQ expression of was analysed in mesenteric lymph node cells by staining with L2 (anti-DQα) and Genox 3.53 (anti-DQβ) followed by rabbit anti-mouse Ig-FITC (Dakopats, Glostrup, Denmark) as second layer. A total of 20,000 events was collected using FACScan. For analysis of TCR V β usage, mesenteric lymph node cells were stained with the following mAb: KJ25 (anti-V β 3; PharMingen, San Diego, CA), KT4-10 (anti-V β 4; PharMingen), F23.1 (anti-V β 8.1,2,3), KT11 (anti-V β 11) and MR12.4 (anti-V β 13). Anti-TCR mAb were either used directly phycoerythrin (PE)-conjugated or were used with PE-conjugated rabbit anti-mouse Ig. FITC-conjugated mAb against CD4 and CD8 were also included in all stainings.
Mouse T cell proliferation assay HLA-DQ8 transgenic mice and negative littermates and NOD and NOD.E transgenic mice were immunized in both hind footpads with 50 µg GAD peptide emulsified in complete Freund's adjuvant. After 10 days popliteal draining lymph nodes were removed and single-cell suspensions prepared in HL-1 serum-free medium (Hycor Biomedical, Irvine, CA) supplemented with L-glutamine (2 mM), 2-mercaptoethanol (5ϫ10 -5 ), penicillin (30 IU) and streptomycin (30 µg/ml). Cells (4ϫ10 -5 ) were cultured in triplicate in 96-well flat-bottomed microculture plates in the presence of GAD peptide, or as a positive control, with 50 µg/ml purified protein derivative of Mycobacterium tuberculosis (PPD) and as a negative control HL-1 medium. Cultures were incubated for 3 days. [ 3 H]Thymidine (0.5 µCi) was added to each well 18 h before termination and cultures were then harvested for counting in a β scintillation counter.
DQ8 mouse T cell lines and cell cultures
T cell lines from immunized lymph nodes were initially cultured as described for proliferation assays in the presence of 50 µg/ml of GAD peptide for 10 days. Then 2ϫ10 5 T cells/well were resuspended in RPMI 1640 medium (Gibco/BRL, Paisley, UK) supplemented with L-glutamine (10 mM), 2-mercaptoethanol (5ϫ10 -5 ), penicillin (30 IU), streptomycin (30 µg/ml), 5% FCS and re-stimulated with 50 µg/ml of GAD peptide in the presence of 5ϫ10 6 irradiated splenocytes. After 72 h stimulation the cytokines IL-2 (20 IU/ml) and IL-4 (2 IU/ml) were added to the medium and cultures incubated for a further 7 days. This concentration of IL-4 is widely used to promote survival of both T h 1 and T h 2 clones (29), and it is substantially below the concentration required to bias development towards a T h 2 response. The 10 day cycle was repeated 4 times. Lines were assayed for HLA-DQ restriction by antigen presentation using either HLA-DQ8 ϩ or HLA-DQ8 -splenocytes and by blocking with anti-class II mAb (as indicated in the Results) added to cultures as affinity purified Ig at 20 µg/ml. Supernatants were assayed for cytokines 7 days after re-stimulation with GAD peptides.
T cell proliferation assays of immunized lymph node cells were established from NOD and NOD.E transgenic mice as described above. Cells were stimulated with GAD peptide. After 66 h stimulation, 50 µl of supernatant was removed from each well to determine cytokine production. The remainder of each microculture was pulsed with [ 3 H]thymidine and cultured for a further 18 h, then incorporated radioactivity was counted. The IL-4, IL-10 and IFN-γ content of the supernatants was measured by specific ELISA, measuring against linear standard curves (Endogen, Cambridge, UK, IFN-γ; R & D Systems, Abingdon, UK, IL-4 and IL-10). Responses of T cell clones specific for peptides 505-519 and 521-535 raised from two DQ8 ϩ patients with IDDM (peptide was added at 10 µg/ml). 
Results
Primary proliferation in diabetic patients and controls to peptides covering regions 161-243 and 473-555 of GAD 65 , and establishment of human T cell clones Of six diabetic patients and seven controls tested, several individuals in both the diseased and control groups responded to epitopes within the region 161-243 and to the 15mer peptide 533-547 (Table 1) . Other epitopes which were recognized by some individuals but were not limited to the diseaseaffected group were 173-187, 493-507 and 505-519. The profile of activity to almost all recognized peptides was identical within pairs of twins. However, peptide 521-535 was recognized by T cells from two of the affected monozygotic twins, but not by their unaffected twins. It was also recognized by T cells from the non-twin patient S1, but not by the two unaffected individuals, S3 and S4. T cell responses to PHA and TT were similar between monozygous twins. Thus only T cell reactivity to GAD 65 521-535 differed between diabetic and non-diabetic subjects. T cell clones were established from DQ8 ϩ patients to two of the peptides, 505-519 and 521-535 (Table 2 ).
GAD 65 epitopes have different binding affinities to HLA-DQ8
Binding affinities to HLA-DQ8 molecules were measured for GAD 65 505-519 and 521-535 with 160-175 and 247-266 as internal controls. These epitopes largely overlap p34 and p35 identified in the NOD mice (3). These epitopes were selected because of a previous report describing significant binding to DQ8 (30) or because we had established T cell clones against them (Fig. 1) (24) . Purity of the HLA-DQ preparation used for binding studies is indicated to the right in Fig. 1 (B and C): anti-DR affinity-purified material hybridizes with the HLA-DR-specific mAb, but no binding is obtained to anti-DQpurified material. The possibility of contamination by DR molecules was further excluded by the observation that no binding was obtained using the DR4 reference binding peptide, hemagglutinin 306-319. As expected GAD 65 247-266 binds DQ with high affinity and confirmed the findings of Kwok et al. (30) . Peptide 160-175 showed a similar binding profile. Conversely peptides 505-519 and 521-535 showed a medium/low to low binding affinity to DQ8 (Fig. 1A) .
Characterization of HLA-DQ8 transgenic mice
Transgenic mice expressed the DQA1*0301 and DQB1*0302 transgenes. Northern analysis of total RNA showed strong DQα transcripts in spleen and thymus, and not in other tissues ( Fig. 2A) . Identical results were seen on hybridization with a DQβ probe (data not shown). By RT-PCR, a small amount of transgene expression was also detectable in kidney and lung (data not shown). The HLA-DQ product was expressed normally at the cell surface as indicated by strong staining of lymph node cells with the mAb L2 (anti-DQα) and Genox 3.53 (anti-DQβ) ( Fig. 2C and E) . In transgenic mice involving the introduction of HLA class II heterodimers our observations are that species-matched pairing is retained, i.e. Aα pairs with Aβ and DQα with DQβ, intra-species pairing not being competitively favoured. The distribution of HLA-DQ transgene expression was analysed in more detail by immunocytochemical co-localization (Fig. 3) . Figure 3(A) shows thymic colocalization (in yellow) of HLA-DQ (in red) and the G8.8 medullary epithelial marker (in green), indicating strong staining of medullary epithelium. The L2 mAb does not stain tissue in non-transgenic mice, having no cross reactivity with H2-A (Fig. 3 and data not shown) . Co-localization with the cortical epithelium marker, CDR1, indicates a typical feint, reticular pattern of staining through the thymic cortex (Fig. 3B) . Transgenic spleen shows staining of IgM ϩ B cells around the lymphoid follicle, pronounced staining of cells in the germinal centre, and relatively limited staining of the T cells, dendritic cells and macrophages within the T cell area (Fig. 3E) . The relative lack of staining in this region is emphasized by the lack of co-localization with mouse CD3 indicated in Fig. 3(H) .
A basic measure of function for a HLA class II transgene expressed normally in the immune system of a transgenic line is the ability to alter selection of the TCR repertoire. This may involve large-scale deletion of particular V β families, generally via mammary tumor virus (MTV) products, or expansions of particular V α or V β families. Analysis of five TCR V β families is shown in Table 3 . HLA-DQ8 transgenic mice had been maintained on a C57BL/10 background carrying MTV 8, 9 and 11. V β 11 ϩ cells, which would be deleted in H2-E ϩ mice carrying these MTV and have been reported deleted in HLA-DQβ single-chain transgenics (31) , are unaffected by the expression of HLA-DQ8. Indeed, after analysing several HLA-DQ transgenic lines, we have observed no cases of DQmediated MTV deletion (Frater and Altmann, unpublished observations). However, a functional effect of HLA-DQ expression was observed here in terms of significantly enhanced positive selection into both CD4 single-positive (SP) and CD8 SP subsets of V β 8.1,2,3 ϩ cells.
T cells from HLA-DQ8 transgenic mice and lines proliferate in response to low-affinity GAD 65 505-519 and 521-535 epitopes Immunodominant GAD 65 epitopes with differential binding affinities for DQ allowed investigation of the relationship between the peptide affinity for a disease-associated class II molecule and immunogenicity. B10.DQ8 transgenic mice and their DQ-negative littermates were immunized with the GAD 65 505-519 and 521-535 epitopes. Ten days later proliferation assays and T cell lines were set up as described in Methods. Although we have previously reported detailed characterization of HLA class II transgenic mouse T cell responses in the presence or absence of a human CD4 transgene, those experiments are not repeated here since we previously showed no enhancement of HLA-restricted responses in the presence of human CD4 (32) . Furthermore, crossing onto an H2-Ab -/-strain would be inappropriate for this analysis since it would result in unpaired H-2Aα chains, predisposing to Aα/ Qβ mixed pairs. Popliteal lymph node cells from both B10.DQ8 transgenic and their transgene negative littermates respond following in vitro challenge with the medium/low-and low- affinity GAD 65 505-519 and 521-535 epitopes (Fig. 4A) . Responses to GAD 521-535 were low in DQ8 transgenic mice and completely negative in non-transgenic B10 controls (Fig. 4A, right) . In the case of GAD 505-519 both transgenic and non-transgenic mice respond, with a slight enhancement in the transgenic group (Fig. 4A, left) . While this response could have contained both HLA-DQ-and H-2A b -restricted T cells, the enhanced proliferative response of transgenic mice indicated that some component of the overall response must be contributed by HLA-DQ-restricted cells. This is confirmed in Fig. 4(B) : after five rounds of re-stimulation using HLA-DQ8 ϩ/ H2-A bϩ splenocytes as antigen-presenting cells, there is outgrowth of a T cell line which is HLA-DQ-restricted such that it recognizes peptide presented by DQ8 ϩ APC (closed circles) but not by DQ8 -APC (open circles). Furthermore these responses can be inhibited by the anti-DQ mAb, L2, but not by an irrelevant mAb (Fig. 4C) . The HLA-DQ-restricted responses to GAD 505-519 (Fig. 4D ) and 521-535 (Fig. 4E) were associated with a strong IFN-γ and IL-10 response, IL-4 being undetectable (data not shown). T cells from NOD and NOD.E transgenic mice proliferate in response to low-affinity GAD 65 505-519 and 521-535 epitopes
The low DQ8 binding affinity epitopes 505-519 and 521-535 largely overlap p34 and p35 identified in the NOD mice (3). Some previous studies of GAD epitope recognition by NOD T cells have analysed the spontaneous response of splenocytes from unimmunized mice while others have relied upon active immunization with peptides in adjuvant. In our study spontaneous responses were variable, so we analysed responses of lymph node cells following immunization in complete Freund's adjuvant. The NOD and NOD.E T cells mount a similar proliferative response in vitro to GAD 65 505-519 (Fig. 5A ). There was, however, a differential proliferative response to the GAD 65 521-535 epitope, the NOD T cells mounting the stronger proliferative response (P Ͻ 0.05 by Student's t-test). Neither the NOD nor NOD.E T cells proliferate in vitro in response to either GAD 65 160-175 or 247-266. These epitopes were chosen because they are recognized by T cells from IDDM patients (10) and NOD mice (6,7) respectively. The recall response to the PPD of M. tuberculosis within the adjuvant was not significantly different between transgenic and non-transgenic mice. Type I diabetes is, therefore, associated with a stronger proliferative response to GAD 65 521-535 in NOD compared to NOD.E transgenic mice. Despite the poor proliferative response of NOD.E transgenic T cells to GAD 65 521-535 both the NOD and NOD.E T cells in vitro produce similar amounts of IFN-γ following re-stimulation with 521-535 (Fig. 5C ). There is, however, a differential production of IL-10 with the NOD T cells not only producing more IL-10 than those of the NOD.E (Fig. 5B) , but also in a linear relationship to increased IFN-γ production (r ϭ 1.000) (Fig.  5D ).
Discussion
Several GAD 65 T cell epitopes have previously been described in diabetes patients, unaffected controls and NOD mice. Our initial approach in the present study was to compare responses to several GAD 65 epitopes in conditions of disease and protection from disease. It should be noted that while this study has focused on differential responses to epitopes towards the C-terminus of the sequence, other T cell epitopes have been identified towards the central region of the protein be an important epitope associated with type I diabetes in both humans and NOD mice. Several GAD 65 epitopes can be recognized by T cells from either diabetic patients or NOD mice, but susceptible and protected individuals are distinguished by their responses to the 521-535 epitope. The differential response between NOD mice and protected NOD.E transgenic mice to this GAD 65 epitope must be a consequence of the difference in expression of H-2E. Whilst the association between differentiated GAD 65 T cell responses and susceptibility to IDDM in the human monozygotic twins mirrors this finding, it clearly cannot be attributed to differences in MHC expression. Several studies indicate that exogenous factors or disease can differentially skew T cell function between identical twins (34, 35) . One study of multiple sclerosis, in particular, showed that after stimulation with MBP or TT, identical twins concordant for the disease selected similar TCR after stimulation with antigen; discordant twins did not (34) . An inherent problem in the multiple sclerosis study and in this present report is the relatively small number of highly selected discordant twins that can be studied.
The disease-related epitope GAD 65 521-535 as well as the epitope 505-519 are recognized by T cells from diabetes patients yet bind to HLA-DQ8 with medium/low or low affinity. The latter peptide overlaps an epitope 509-528 (p34), identified in 4-week-old NOD mice as the earliest peptide recognized by self-reactive T cells. The low affinity of these epitopes for DQ8 is contrary to the logic of some other studies in which autoimmune disease epitopes have been sought by the criterion of high-affinity binding to disease-associated HLA alleles (14, 15) . However, Ac-MBP 1-11 which is the encephalitogenic epitope in EAE of H2-u mice, binds H2-A u with undetectably low affinity, whereas MBP 111-129, the immunodominant epitope in DR4 multiple sclerosis patients, is a low-affinity binder (17) and the dominant peptide of the Goodpasture disease antigen, the NC1 domain of α2 type IV collagen, is also a low-affinity binder (18) . The low-affinity self-peptides hypothesis argues that a very fast off-rate may impede negative selection and allow the survival of selfreactive clones (19) . The affinity of HLA-DQ8 for GAD 65 505-519 and 521-535 may lie below the threshold for the induction of central tolerance.
HLA-DQ-restricted T cell responses to candidate self antigens are difficult to study in man. Furthermore patients mount heterogeneous responses to self epitopes and it is ultimately difficult to prove that any given response is a cause of disease. Analysis of T cell responses in identical twins discordant for diabetes refines the process of identifying disease-associated epitopes. However, testing whether a given HLA allele presents a specific epitope to self-reactive T cells or positively selects populations of self-reactive TCR is difficult; HLA-DQ products are generally poorly expressed by peripheral APC, hence DQ-restricted compared to DR-restricted T cells are rarely identified (36) . Modelling of responses in HLA transgenic mice could resolve these problems and shed light on the interactions leading to disease. There were initial concerns that the relevance of HLA transgenic mouse studies might be limited due to problems in generating HLA-restricted responses in the context of a murine immune system, and a lack of direct comparability between the mouse and human TCR populations interacting with any given peptide-HLA complex. HLA-restricted responses in transgenic mice have now been widely reported and in many cases the immunodominant epitopes recognized by T cells of transgenic mice have matched the epitopes of human T cells restricted by the same product (37, 38) . Furthermore, a study using HLA-DQ8 transgenic mice reported HLA-DQ-restricted responses to bovine type II collagen associated with a severe, transgenedependent polyarthritis (39) . C57BL/10 mice do not develop insulitis or diabetes because they lack the non-MHC genetic background for disease susceptibility, yet C57BL/10 and B10.DQ8 transgenic mice both respond strongly to GAD 505-519, the transgenic mice mounting the greater response. Furthermore, B10.DQ8 mice respond to GAD 521-535 while C57BL/10 mice do not. The responses to these GAD epitopes are similar to those of NOD mice, although in some NOD T cell studies responses could be detected spontaneously without the need for prior immunization of peptide in adjuvant (3, 4) . The strong response that healthy mice make to these self epitopes confirms that if anti-GAD T cell responses are necessary for the development of disease, they are not sufficient (40, 41) .
There is evidence, drawn largely from studies of NOD, mice that T h 1 cytokines are implicated in the pathogenesis of IDDM. Anti-IFN-γ antibodies can prevent the development of diabetes induced in NOD mice either by cyclophosphamide or adoptive transfer of diabetogenic cells (42, 43) , although NOD mice lacking IFN-γ are nevertheless susceptible to insulitis and diabetes (44) . Tolerogenic administration of GAD 65 peptides induces a T h 2 response which prevents diabetes in NOD mice (45) . B10.DQ8 T cell lines responding to GAD 65 505-519 in a HLA-DQ-restricted manner produce IFN-γ and IL-10 but undetectable IL-4. While IL-10 release has in some contexts been associated with a T h 2 response, it can also commonly be produced in association with IFN-γ by T h 1-like cells (46, 47) and it has been suggested that IL-10 may have a central role in the evolution of diabetes in NOD mice (48) . In responses of NOD and NOD.E mice to GAD 65 521-535, both produced a IFN-γ response, the major difference between susceptible and protected mice being in the strong, IFN-γ-linked IL-10 response in the susceptible NOD mice.
In summary, we have demonstrated that GAD epitopes with low affinity for the DQ8 diabetes-associated product can elicit T cell responses in humans and in HLA transgenic mice. Furthermore, T cell responses to one of these epitopes, GAD 521-535, distinguishes between susceptible and protected individuals.
